Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY SAN

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1679565279
CMS profile
257683
Location
GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$9,756.10

86 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY SAN

NPI 1679565279 · CMS profile ID 257683

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

GREENVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679565279?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY SAN, NPI 1679565279, CMS profile ID 257683. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679565279?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GREGORY SAN, NPI 1679565279, CMS profile ID 257683. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679565279?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GREGORY SAN, NPI 1679565279, CMS profile ID 257683, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–86 of 86 matching records. This page contains 36 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1679565279?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

86 matching records · $9,756.10 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 86 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–86 of 86.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $11.9905/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825340293 CMS
Janssen Pharmaceuticals, Inc $15.0605/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788553215 CMS
Novartis Pharmaceuticals Corporation $15.5205/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813227001 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $10.2705/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768805608 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $750.0005/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763659598 CMS
Merck Sharp & Dohme Corporation $23.4605/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848657213 CMS
Janssen Pharmaceuticals, Inc $11.4005/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788553213 CMS
Janssen Pharmaceuticals, Inc $13.0305/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788553243 CMS
Janssen Pharmaceuticals, Inc $10.1805/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788553245 CMS
Novartis Pharmaceuticals Corporation $17.0805/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226989 CMS
Novartis Pharmaceuticals Corporation $13.5804/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226993 CMS
AstraZeneca Pharmaceuticals LP $13.4304/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830052593 CMS
AstraZeneca Pharmaceuticals LP $12.8504/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829314751 CMS
Janssen Pharmaceuticals, Inc $19.7904/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788553219 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.1804/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763659596 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $11.3604/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768805606 CMS
Bayer HealthCare Pharmaceuticals Inc. $15.2403/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789171937 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $12.3603/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768805604 CMS
Novartis Pharmaceuticals Corporation $20.6103/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226985 CMS
Abbott Laboratories $23.5103/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818443157 CMS
Abbott Laboratories $23.1103/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818441949 CMS
Lilly USA, LLC $750.0003/10/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819099723 CMS
Amarin Pharma Inc. $12.0603/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815276275 CMS
AstraZeneca Pharmaceuticals LP $13.5203/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829575301 CMS
Novartis Pharmaceuticals Corporation $22.5802/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813226981 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $11.3602/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768805602 CMS
Abbott Laboratories $20.1302/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818423095 CMS
Abbott Laboratories $24.0102/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818420299 CMS
Amarin Pharma Inc. $18.3502/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815382129 CMS
Janssen Pharmaceuticals, Inc $9.2802/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788553207 CMS
Janssen Pharmaceuticals, Inc $22.2002/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788553217 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $12.7902/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768805600 CMS
Amgen Inc. $14.5201/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825340289 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $10.3101/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768805598 CMS
Janssen Pharmaceuticals, Inc $17.4701/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788553237 CMS
AstraZeneca Pharmaceuticals LP $31.4401/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829474133 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $28,237.32 224
PY2020 $10,085.65 56
PY2021 $9,756.10 86
PY2022 $16,358.35 103
PY2023 $6,904.50 41
PY2024 $9,401.84 42
PY2025 $7,241.98 27

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $173,564.84 145
PY2024 Principal investigator $54,528.36 4
PY2023 Principal investigator $18,543.15 2
PY2022 Principal investigator $26,682.74 3
PY2021 Principal investigator $67,928.93 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

145 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $18.48 12/31/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629883
Principal investigator 1 Boehringer Ingelheim International GmbH $49.00 12/31/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629885
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 12/17/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637529
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 12/17/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637531
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 12/11/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629867
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 12/11/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629869
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629863
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629865
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 11/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629845
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 11/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629847
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 11/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629849
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 11/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629851
Principal investigator 1 Boehringer Ingelheim International GmbH $400.00 11/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629853
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 11/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629855
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 11/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629857
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 11/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629859
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 11/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629861
Principal investigator 1 Boehringer Ingelheim International GmbH $412.00 11/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629829
Principal investigator 1 Boehringer Ingelheim International GmbH $412.00 11/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629831
Principal investigator 1 Boehringer Ingelheim International GmbH $436.00 11/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629833
Principal investigator 1 Boehringer Ingelheim International GmbH $412.00 11/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629835
Principal investigator 1 Boehringer Ingelheim International GmbH $412.00 11/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629837
Principal investigator 1 Boehringer Ingelheim International GmbH $436.00 11/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629839
Principal investigator 1 Boehringer Ingelheim International GmbH $136.00 11/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629841
Principal investigator 1 Boehringer Ingelheim International GmbH $436.00 11/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629843
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 11/11/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994531
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629825
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629827
Principal investigator 1 Boehringer Ingelheim International GmbH $568.16 10/31/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629871
Principal investigator 1 Boehringer Ingelheim International GmbH $43.56 10/31/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629873
Principal investigator 1 Boehringer Ingelheim International GmbH $196.68 10/31/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629875
Principal investigator 1 Boehringer Ingelheim International GmbH $171.60 10/28/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629877
Principal investigator 1 Boehringer Ingelheim International GmbH $18.48 10/28/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629879
Principal investigator 1 Boehringer Ingelheim International GmbH $48.92 10/28/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629881
Principal investigator 1 Boehringer Ingelheim International GmbH $379.62 10/27/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629887
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 10/27/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629889
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 10/27/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629891
Principal investigator 1 Boehringer Ingelheim International GmbH $7.52 10/27/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629893
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 10/22/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994529
Principal investigator 1 Boehringer Ingelheim International GmbH $3,096.00 10/20/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629819
Principal investigator 1 Boehringer Ingelheim International GmbH $436.00 10/20/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629821
Principal investigator 1 Boehringer Ingelheim International GmbH $3,476.00 10/20/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629823
Principal investigator 1 Boehringer Ingelheim International GmbH $3,200.00 10/02/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637513
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 10/02/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637515
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 10/02/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637517
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 10/02/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637519
Principal investigator 1 Boehringer Ingelheim International GmbH $3,300.00 10/02/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637521
Principal investigator 1 Boehringer Ingelheim International GmbH $14,750.00 10/02/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637523
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/02/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637525
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/02/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637527
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629815
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629817
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629791
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629793
Principal investigator 1 Boehringer Ingelheim International GmbH $436.00 08/20/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629813
Principal investigator 1 Boehringer Ingelheim International GmbH $3,997.00 08/13/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629799
Principal investigator 1 Boehringer Ingelheim International GmbH $3,540.00 08/13/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629801
Principal investigator 1 Boehringer Ingelheim International GmbH $2,344.00 08/13/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629803
Principal investigator 1 Boehringer Ingelheim International GmbH $436.00 08/13/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629805
Principal investigator 1 Boehringer Ingelheim International GmbH $3,476.00 08/13/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629807
Principal investigator 1 Boehringer Ingelheim International GmbH $436.00 08/13/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629809
Principal investigator 1 Boehringer Ingelheim International GmbH $436.00 08/13/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629811
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629787
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629789
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 07/28/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637507
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 07/28/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637509
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 07/28/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637511
Principal investigator 1 Boehringer Ingelheim International GmbH $3,096.00 07/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629773
Principal investigator 1 Boehringer Ingelheim International GmbH $2,280.00 07/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629775
Principal investigator 1 Boehringer Ingelheim International GmbH $351.00 07/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629781
Principal investigator 1 Boehringer Ingelheim International GmbH $1,997.00 07/23/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629777
Principal investigator 1 Boehringer Ingelheim International GmbH $591.00 07/23/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629779
Principal investigator 1 Boehringer Ingelheim International GmbH $132.00 07/23/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629783
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 07/23/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629785
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 07/09/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220994882
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629795
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629797
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629769
Principal investigator 1 Boehringer Ingelheim International GmbH $4.20 06/24/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629771
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 06/04/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629749
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 06/04/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629751
Principal investigator 1 Boehringer Ingelheim International GmbH $4,070.00 06/04/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629753
Principal investigator 1 Boehringer Ingelheim International GmbH $351.00 06/04/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629755
Principal investigator 1 Boehringer Ingelheim International GmbH $2,944.00 06/04/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629757
Principal investigator 1 Boehringer Ingelheim International GmbH $351.00 06/04/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629759
Principal investigator 1 Boehringer Ingelheim International GmbH $3,467.00 06/04/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629761
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 06/03/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994527
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629745
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629747
Principal investigator 1 Boehringer Ingelheim International GmbH $68.00 05/23/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629737
Principal investigator 1 Boehringer Ingelheim International GmbH $1,997.00 05/23/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629739
Principal investigator 1 Boehringer Ingelheim International GmbH $40.45 05/08/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637549
Principal investigator 1 Boehringer Ingelheim International GmbH $62.39 05/08/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637551
Principal investigator 1 Boehringer Ingelheim International GmbH $340.00 05/07/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629735
Principal investigator 1 Boehringer Ingelheim International GmbH $263.22 05/07/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637533
Principal investigator 1 Boehringer Ingelheim International GmbH $123.97 05/07/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637535
Principal investigator 1 Boehringer Ingelheim International GmbH $57.19 05/07/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637537
Principal investigator 1 Boehringer Ingelheim International GmbH $38.36 05/07/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637539
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 05/07/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637541
Principal investigator 1 Boehringer Ingelheim International GmbH $60.06 05/07/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637543
Principal investigator 1 Boehringer Ingelheim International GmbH $20.00 05/07/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637545
Principal investigator 1 Boehringer Ingelheim International GmbH $124.99 05/07/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637547
Principal investigator 1 Boehringer Ingelheim International GmbH $303.60 05/07/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637555
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629741
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629743
Principal investigator 1 Boehringer Ingelheim International GmbH $412.00 04/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629727
Principal investigator 1 Boehringer Ingelheim International GmbH $3,823.00 04/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629729
Principal investigator 1 Boehringer Ingelheim International GmbH $2,280.00 04/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629731
Principal investigator 1 Boehringer Ingelheim International GmbH $479.52 04/23/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629763
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 04/23/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629765
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629767
Principal investigator 1 Boehringer Ingelheim International GmbH $408.00 04/11/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629733
Principal investigator 1 Boehringer Ingelheim International GmbH $565.34 04/04/2025 Non-covered Recipient Entity
Poinsett Family Practice
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220637553
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629723
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629725
Principal investigator 1 Boehringer Ingelheim International GmbH $239.76 03/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629721
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8,346.20 03/21/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220994525
Principal investigator 1 Boehringer Ingelheim International GmbH $4,070.00 03/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629687
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 03/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629689
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 03/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629691
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 03/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629693
Principal investigator 1 Boehringer Ingelheim International GmbH $4,070.00 03/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629695
Principal investigator 1 Boehringer Ingelheim International GmbH $2,944.00 03/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629697
Principal investigator 1 Boehringer Ingelheim International GmbH $2,280.00 03/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629699
Principal investigator 1 Boehringer Ingelheim International GmbH $3,467.00 03/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629701
Principal investigator 1 Boehringer Ingelheim International GmbH $47.00 03/19/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629705
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629683
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629685
Principal investigator 1 Boehringer Ingelheim International GmbH $4,070.00 02/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629675
Principal investigator 1 Boehringer Ingelheim International GmbH $3,467.00 02/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629677
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 02/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629713
Principal investigator 1 Boehringer Ingelheim International GmbH $584.00 02/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629715
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 02/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629717
Principal investigator 1 Boehringer Ingelheim International GmbH $15.04 02/25/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629719
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629679
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629681
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629703
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 01/27/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629707
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 01/27/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629709
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 01/27/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629711
Principal investigator 1 Boehringer Ingelheim International GmbH $4,070.00 01/24/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629667
Principal investigator 1 Boehringer Ingelheim International GmbH $3,467.00 01/24/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629669
Principal investigator 1 Boehringer Ingelheim International GmbH $2,280.00 01/22/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629665
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629671
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Carolina Cardiology Consultants-Greenville
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220629673